Superworth

Galectin Therapeutics price to book ratio GALT

Market value divided by the book value of the company's net assets, since 2011.

Today, Oct 23, 2026
n/m
not a meaningful number
Last meaningful
90.4×
May 2022
10-year median
10.9×
10-year range
2.2× to 200×
Peer median
1.9×

Galectin Therapeutics' price to book ratio is not a meaningful number today: shareholders' equity was zero, negative or not reported, so price to book does not exist.

It was last meaningful in May 2022, at 90.4×.

On the days it had one over the last ten years, its median was 10.9×, from 2.2× in Apr 2020 to 200× in Jun 2018.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
202290.4×13.7×116×
202116.3×3.8×21.2×
20204.3×2.2×5.4×
20193.4×3.4×45.0×
201821.4×19.7×200×
2017126×2.8×126×
20162.8×2.0×10.7×
20153.1×2.5×4.3×
20143.2×3.2×196×
2013114×10.7×131×
201210.8×4.1×91.8×
201189.9×68.4×92.7×

Against its peers

Companies in Drug Manufacturers - General nearest Galectin Therapeutics' size, closest first, today.

CompanyPrice to book ratio
GALTGalectin Therapeuticsn/m
ARVNArvinas0.8×
NATRNatures Sunshine Products1.3×
PBYIPuma Biotechnology4.1×
IRWDIronwood Pharmaceuticalsn/m
ZVRAZevra Therapeutics2.7×
CRMDCorMedix1.3×
COLLCollegium Pharmaceutical2.4×
ABUSArbutus Biopharma3.2×
AMPHAmphastar Pharmaceuticals1.4×
OMEROmerosn/m
Peer median1.9×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Galectin Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.